showed that Lactobacillus brevis CD2 lozenges reduced the incidence of grade III and IV anticancer therapy‐induced oral mucositis due to its potential anti‐inflammatory activity in patients undergoing hematopoietic stem cell transplantation [31]. This evidence concerns the gene CD2 and oral mucositis.